Read or download the official PDF of this gazette notification issued by the Ministry of Science and Technology on 19th August 2026. Classified under Press Release.
Executive Summary
The Technology Development Board (TDB), under the Department of Science & Technology, has extended financial assistance to OrthoGraft Pvt. Ltd. to commercialize advanced, indigenous tissue-derived biological dressings. Announced on August 19, 2026, the project aims to establish manufacturing capabilities for wound-care solutions targeting chronic wounds, diabetic foot ulcers, and burns. This initiative focuses on translating proprietary tissue-processing technology into clinically relevant products to strengthen India’s medical technology ecosystem.
Key Points / Main Content
Project Objectives and Scope
Establishment of a production set-up for indigenous biological dressings designed for difficult-to-heal wounds.
Commercialization of proprietary technology that transforms biomedical tissue into shelf-stable, high-value tissue substitutes.
Focus on clinical applications including burns, chronic wounds, and diabetic foot ulcers.
Technological Innovations
Utilization of an advanced tissue-processing methodology that ensures effective cellular removal while preserving bioactive components and tissue quality.
Development of products with improved tensile strength and a Moisture Vapour Transmission Rate (MVTR) comparable to existing commercial moist wound dressings.
Integration of tissue engineering and biomaterials science to maintain the structural characteristics of native tissue.
Infrastructure and Compliance
Strengthening of production infrastructure at a bio-incubation facility leased within the Savli Technology Business Incubator, Vadodara.
Secured requisite licenses from the CDSCO for the manufacture of medical devices for testing purposes.
Utilization of two granted US patents and multidisciplinary know-how in tissue processing.
Collaborations and Research
Partnerships with institutions of national importance, such as IIT Ropar, for technology development and translation.
Ongoing exploration of collaborations with tertiary-care hospitals and medical institutions for clinical translation.
Impact Analysis
OrthoGraft Pvt. Ltd.Impact
The company receives financial assistance to scale its proprietary R&D into a commercial manufacturing operation. It gains access to biotechnology infrastructure and the ability to build an indigenous portfolio of advanced tissue substitutes.
Action Required
The company must strengthen its production infrastructure at the Savli Technology Business Incubator and continue its clinical translation and development efforts with partner hospitals.
Healthcare Providers and PatientsImpact
Tertiary-care hospitals and medical institutions will gain access to high-quality, indigenous biological wound-care solutions. Patients suffering from chronic wounds and burns will have improved treatment options.
Action Required
Hospitals and medical institutions are encouraged to collaborate with OrthoGraft for the clinical translation and further development of the technology platform.
Technology Development Board (TDB) / DSTImpact
TDB fulfills its mandate of supporting Indian startups in translating specialized know-how into manufacturable products, thereby enhancing India's global competitiveness in the medical technology sector.
Action Required
TDB will provide the sanctioned financial assistance and oversee the project's progress toward indigenous manufacturing and commercialization.
Key Entities Referenced
Technology Development Board (TDB): A statutory body under the Department of Science & Technology that provided financial assistance for the project to commercialize indigenous tissue-derived biological dressings.
OrthoGraft Pvt. Ltd.: A medical device startup receiving financial support to establish manufacturing capabilities for advanced wound-care products and tissue substitutes.
Department of Science & Technology (DST): The primary central ministry department overseeing the Technology Development Board and the commercialization of the medical technology project.
Central Drugs Standard Control Organisation (CDSCO): The national regulatory authority that issued requisite licenses to the startup for the manufacture of medical devices for testing purposes.
Savli Technology Business Incubator, Vadodara, Gujarat: The location where the company is establishing its production infrastructure and bio-incubation facility for medical device development.
Ministry of Science & Technology
TDB-DST Supports OrthoGraft Pvt. Ltd.,
Vadodara, Gujarat for Commercialization of
Advanced Tissue-Derived Biological Dressings
for Wound Care
प्रव तथ: 19 AUG 2026 4:38PM by PIB Delhi
Turning advances in tissue engineering into clinically relevant solutions for difficult-to-heal wounds, the
Technology Development Board (TDB), Department of Science & Technology (DST), Government of India,
has extended financial assistance to M/s OrthoGraft Pvt. Ltd. Vadodara, Gujarat for the project titled
“Production Set-up for Advanced Tissue Derived Biological Dressings.” Through TDB’s support, the
company will establish manufacturing capabilities for indigenous biological dressings intended for clinical
wound-care applications, including chronic wounds, diabetic foot ulcers and burns.
OrthoGraft is a DPIIT-recognised medical device startup engaged in developing tissue substitutes for
clinical reconstruction and functional repair. The company is developing proprietary technologies for
processing viable human tissue into shelf-stable tissue substitutes while retaining key biological and
structural characteristics of the native tissue that are relevant to the wound-healing process.
At the core of the project is an advanced tissue-processing methodology designed to achieve effective
cellular removal while preserving tissue quality and bioactive components. The resulting biological
dressings are being developed with improved tensile strength, maximal retention of bioactive factors and
Moisture Vapour Transmission Rate (MVTR) comparable to commercially available moist wound dressings.
An important aspect of the technology is its approach towards transforming suitable biomedical tissue
material into high-value, clinically relevant biological dressings. The project combines tissue engineering,
biomaterials science and specialized processing to develop advanced wound-care products with potential
application in the management of chronic and hard-to-heal wounds.
With TDB assistance, OrthoGraft will strengthen its production infrastructure at the Savli Technology
Business Incubator, Government of Gujarat, Vadodara, where the company has leased a bio-incubation
facility. The location provides access to biotechnology R&D infrastructure required for medical device
development and translation. The company has also obtained requisite licences from CDSCO for
manufacture of medical devices for testing purposes and is exploring collaborations with tertiary-care
hospitals and medical institutions for further development and clinical translation of the technology.
The company has developed multidisciplinary know-how in tissue processing and tissue substitutes and
currently holds two granted US patents. It is also working with institutions of national importance, including
IIT Ropar, and multispecialty hospitals towards development and translation of its technology platform.
OrthoGraft has previously participated as an industry startup partner in Government of India-supported
multi-institutional R&D and commercialization projects.Speaking on the occasion, Shri Rajesh Kumar Pathak, Secretary, TDB, stated, “Advanced biomaterials
and tissue-engineered products represent an important frontier for India’s medical technology ecosystem.
TDB’s support to OrthoGraft is aimed at enabling an Indian startup to translate its tissue-processing know-
how into commercially manufacturable wound-care products. Such technologies can strengthen indigenous
capabilities in advanced healthcare materials while creating pathways for Indian innovations to compete in
global markets.”
Expressing gratitude for TDB’s support, the leadership of OrthoGraft Pvt. Ltd. stated that the assistance will
help the company establish dedicated production capabilities and accelerate the translation of its proprietary
tissue-processing platform into clinically relevant products. The company aims to build an indigenous
portfolio of advanced tissue substitutes and contribute towards making high-quality biological wound-care
solutions more widely available.
******
NKR/FT/AK
(रलीज़ आईडी: 2301192) आगंतुक पटल : 732
इस वज्ञ को इन भाषाओ ंम पढ़: Urdu , ही , Tamil